🟢 86/100

This product is generally safe

  • Folic Acid: 400mg is 400.0× the Tolerable Upper Intake Level (1.0mg)
  • Contains proprietary blend — exact ingredient amounts not disclosed
  • 44% of ingredients have research evidence
C Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Folic Acid: 400mg is 400.0× the Tolerable Upper Intake Level (1.0mg)
ℹ️ Contains proprietary blend — exact ingredient amounts not disclosed

Label Data

60 mL Serving Size
Other Combinations Product Type
44% Evidence Coverage

Supplement Facts — Evidence Check

Calories
5 Calorie(s)
Total Carbohydrates
33 mg (165% DV)
✅ 2.4× RDA — within safe limits 📚 193 studies (Tier A: 5, B: 63)
RDA 14mg This product: 33mg UL 35mg
40 mg (2000% DV)
📊 30.8× RDA — above typical dose (UL: 100 mg) 📚 113 studies (Tier A: 3, B: 35)
RDA 1.3mg This product: 40mg UL 100mg
400 mg (10% DV)
⚠️ Exceeds Tolerable Upper Intake Level by 400.0× (UL: 1.0 mg) 📚 225 studies (Tier A: 10, B: 105)
RDA 0.4mg This product: 400mg UL 1.0mg
500 mg (8333% DV)
📊 208333.3× RDA — above typical dose 📚 138 studies (Tier A: 1, B: 44)
RDA 0.0024mg This product: 500mg
Sodium
5 mg (1% DV)
Potassium
10 mg (1% DV)
Proprietary Blend
2000 NP

Other Ingredients

Water, Filtered Natural Flavors Sucralose Potassium Sorbate Sodium Benzoate

Label Claims — Verification

All Other
Structure/Function
All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Adult Male (18-50 Years)

Product Information

📋 Directions for Use

Shake well

🧪 Formulation Notes

Maximum size No headache 100% Satisfaction guaranteed XXX Power

Additional Information

100% Strong man approved

Refrigerate after opening

Product Details

DSLD Entry Date 2024-07-25
Product Type Other Combinations
Form Liquid
Brand Unknown
DSLD ID 313352
Data Updated 2026-04-11

Research Evidence

241 Research Sources
55 Avg Quality Score
113 Meta Analysis
75 Systematic Review
32 Rct
11 Clinical Trial
3 Other
3 Regulatory Source
1 Cochrane Review
1 Narrative Review
1 Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016
View all evidence for Niacin →

Compare Similar Products

View all Niacin products →